Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

JERUSALEM, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT(®), today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange and to become dual-listed for trade on both the Nasdaq and TASE markets.

“After the astounding achievements that Alpha Tau has made these last few years, it brings me great pride to say: we are coming home,” commented Uzi Sofer, CEO of Alpha Tau. “The Israeli investor market has been expressing ever-growing interest of late in our progress and in the potential of our technology, and we have received many requests from the local investor base to offer them the opportunity to trade in local currency and business hours as we continue to grow. This is a very exciting step for the Company and we are thrilled to be a part of the thriving Israeli market ecosystem.”